News Briefs: June 14, 2021

CMS’ supplemental medical review contractor (SMRC) is now doing postpayment reviews of Medicare claims for electrodiagnostic (EDX) testing axial muscles and spinal levels with 2019 dates of service, according to its website.[1]

A Maryland physician pleaded guilty to conspiracy to violate the Anti-Kickback Statute in connection with a scheme to take payments from the drug manufacturer Insys Therapeutics Inc. in return for prescribing Subsys, a fentanyl spray it makes for breakthrough pain in cancer patients, for off-label purposes, the U.S. Attorney’s Office for the District of Maryland said June 10.[2] Howard Hoffberg, M.D., of Reisterstown, Maryland, was the associate medical director and part-owner of Rosen-Hoffberg Rehabilitation and Pain Management. “In order to conceal and disguise that kickbacks and bribes were being paid to Hoffberg to prescribe Subsys, Insys falsely designated the payments to Hoffberg as ‘honoraria’ for purportedly providing educational programs about Subsys (the ‘Speakers Bureau Program’),” said the U.S. Attorney’s Office for the District of Maryland. “As part of the scheme, through January 2018 Hoffberg prescribed Subsys to patients of the Practice who were not suffering from cancer, some of whose insurance coverage was paid for, in whole or in part, by a federal healthcare program.” The HHS Office of Inspector General recently warned about speaker programs in a special fraud alert.[3]

This document is only available to subscribers. Please log in or purchase access.
 


Would you like to read this entire article?

If you already subscribe to this publication, just log in. If not, let us send you an email with a link that will allow you to read the entire article for free. Just complete the following form.

* required field